Assets for partnering or out-license:
A differentiated biparatopic PD-1 antagonist which ‘handcuffs’ PD-1 and demonstrates significantly enhanced in vivo efficacy over commercial stage, IgG-based PD-1 antagonists.
A novel bispecific PD-1 x LAG-3 antagonist designed to deliver highly potent simultaneous dual checkpoint blockade in patients non-responsive to PD-1 blockade alone with significant synergy over mixtures of conventional anti-PD-1 and anti-LAG-3.
A half-life extended biparatopic PSMA-specific Humabody® Drug Conjugate (HDC) demonstrating superior tumour targeting, enhanced internalisation and highly efficient accumulation in target-positive tumours.
To discuss and explore partnering opportunities, contact email@example.com